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I t is estimated that between 2.2 and 3.2 million peopleare infected with hepatitis C virus (HCV) in the
United States.1 For more than 20 years, the mainstay of
HCV treatment has been interferon (IFN) alfa, a
nonspeciﬁc immunomodulatory antiviral cytokine, and
ribavirin (RBV). This regimen had limited efﬁcacy and
was poorly tolerated. Because of this, therapy was not
widely deployed and the majority of patients with HCV
infection remained untreated.2 In December 2013,
sofosbuvir (SOF), an inhibitor of the HCV NS5B RNA
polymerase, was approved by the U.S. Food and Drug
Administration, and thus began an era of all-oral IFN-
free HCV therapies. Currently approved direct-acting
antiviral (DAA) therapies target 1 of 3 viral proteins,
the NS5B polymerase, the NS3/4A protease, or the
NS5A protein (Table 1). These agents profoundly
inhibit viral replication and, when used in combina-
tion, can produce viral clearance without dependence
on IFN.3
DAA regimens offer signiﬁcantly increased efﬁcacy,
shorter duration of therapy, and dramatically improvede authors contributed equally to this work.
International Reports (2016) 1, 135–143side effect proﬁles. Real-world data demonstrate cure
rates of more than 90% with combination therapy
consisting of SOF and simeprevir for genotype 1 in-
fections, which is similar to the results from the phase
III clinical trials.4–6 The IFN-free DAA combinations of
SOF plus simeprevir and SOF plus RBV are extremely
well tolerated both in clinical trials and in real-world
patient experiences, with the most common side ef-
fects being headache, fatigue, and nausea.6 Mild anemia
was observed only in regimens containing RBV.
Autoimmune phenomena are well described sequela
of IFN-based therapies for HCV infection7–9; IFN may
aggravate preexisting autoimmunity, unmask previ-
ously silent autoimmune processes, or even cause the
emergence of de novo autoimmune disease.8,10 The
mechanism is thought to be mediated by the effect of
IFN on modulation of the host’s immune system or as a
result of molecular mimicry.11 However, autoimmune
syndromes are not currently described in patients
receiving all-oral IFN-free DAA therapies. These regi-
mens directly target viral replication and therefore
have not been considered “immunomodulatory.” In
this series we report on 3 cases of patients undergoing
HCV therapy with SOF-based DAA therapy in whom a
biopsy-proven lupus-like immune complex–mediated
glomerulonephritis developed.135
Table 1. Currently FDA-approved direct-acting antiviral agents
NS5B polymerase
inhibitors
NS3/4A protease
inhibitors NS5A inhibitors
Sofosbuvir Simeprevir Daclatasvir
Dasabuvir Paritaprevir
Grazoprevir
Ledipasvir
Ombitasvir
Elbasvir
FDA, U.S Food and Drug Administration.
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Case 1
The ﬁrst patient is a 51-year-old white female with a
medical history signiﬁcant for HCV genotype 3a
infection complicated by cirrhosis with a Model for
End-Stage Liver Disease (MELD) score of 10, Child-
Pugh class A, who was referred for treatment of HCV
infection (Figure 1a and Tables 2 and 3). Her baselineFigure 1. Creatinine trend over time in cases 1, 2, and 3. The clinical c
complex–mediated glomerulonephritis are shown. The time during which
(DAA) is shown in shaded gray. AZA, azathioprine; CVVH, continuous veno
mycophenolate mofetil; Pred, prednisone; RBV, ribavirin; SIM, simeprevir;
136kidney function was normal; her serum creatinine level
was 0.72 mg/dl, and her estimated glomerular ﬁltration
rate was >60 ml/min per 1.73 m2. Cirrhosis was diag-
nosed on the basis of a liver biopsy and previously
failed attempts to eradicate HCV with pegylated IFN
and RBV in 2002. The patient began antiviral therapy
with SOF, 400 mg daily, and weight-based RBV (1000
mg daily) for a total of 24 weeks. Her other medications
were spironolactone, 50 mg daily, and furosemide, 20
mg taken as needed for edema. During the course of
antiviral therapy, she experienced mild nausea and
diarrhea. Otherwise, no other adverse effects were
noted. Twelve weeks after treatment she achieved
sustained virological response with an undetectable
viral load. Three months after completing treatment,
she presented to her primary doctor with complaints of
rash and pruritus of the arms, abdomen, and thighs.
The rash was morbilliform with papules involving bothourse of the ﬁrst (a), second (b), and third (c) cases with immune
the patient was receiving the initial course of direct-acting antiviral
venous hemoﬁltration; ICU, intensive care unit; LDV, ledipasvir; MMF,
SOF, sofosbuvir.
Kidney International Reports (2016) 1, 135–143
Table 2. Summary of cases of lupus-like immune complex glomerulonephritis
Case Patient characteristics Clinical presentation Immunosuppression Outcome
1  51-year-old Asian female
Genotype 3a, viral load 3.6  105
 Treatment experienced
(PEG-IFN/RBV)
 Cirrhosis diagnosed by biopsy
Morbilliform rash
 Elevated liver function test results
 Rising creatinine level
 Proteinuria and hematuria
Methylprednisolone, 500 mg i.v.  3 d,
followed by prednisone, 60 mg daily
 Rapid improvement in renal function
 Achieved SVR12
 Death from sepsis, fungal pneumonia,
and empyema
2  56-year-old white female
Genotype 1b, viral load 2.8  106
 Treatment experienced
(PEG-IFN/RBV)
 Cirrhosis diagnosed by allograft
biopsy
 Joint pain
 Rising creatinine level
 Hematuria and leukocyturia
Methylprednisolone, 250 mg i.v.  3 d,
followed by prednisone, 60 mg daily
 Prednisone rapidly decreased to 20 mg
daily because of delirium, then tapered
off over the next 4 wk
MMF maintenance therapy, 250 mg
twice daily  5 mo
 Rapid improvement in renal function
 Relapse of HCV viremia, retreated with
sofosbuvir and ledipasvir
 Relapse of joint pain with retreatment,
steroids and MMF restarted with
improvement
 Achieved SVR12
3  47-year-old Hispanic female
Genotype 1, viral load 8.4  104
 Treatment experienced (IFNa)
 Cirrhosis clinically diagnosed
 Rash (face, chest, and hands)
 Back pain, fatigue
 Rising creatinine level
 Proteinuria and hematuria
Methylprednisolone, 250 mg i.v.  3 d,
followed by prednisone, 60 mg daily
 Rituximab, 1000 mg i.v. weekly x 3
 Rapid improvement in renal function
 Achieved SVR12
 Death from bacteremia, bacterial
pneumonia
d, day(s); HCC, hepatocellular carcinoma; HCV, hepatitis C virus; IFNa, interferon alfa; LT, liver transplant; MMF, mycophenolate mofetil; PEG-IFN, pegylated interferon; mo, month(s);
RBV, ribavirin; SVR12, sustained virological response at 12 weeks; wk, week(s).
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noted on physical examination. Her liver function test
results were elevated, with an alanine aminotransferase
level of 1194 U/l, aspartate aminotransferase level of
1608 U/l, alkaline phosphatase level of 179 U/l, and
total bilirubin of 6.0 U/l. She was admitted to the
hospital and a liver biopsy was performed; it demon-
strated panlobular hepatitis against a background of
cirrhosis. The differential diagnosis of this histopath-
ologic lesion included acute viral injury, immune-
mediated drug reaction, and autoimmune hepatitis.
Her serologic work-up results were abnormal, with a
positive antinuclear antibody test result (a titer of 1:320
titer) and positive smooth muscle antibody test result (a
titer of 1:80). The results of all available serological
tests before and after treatment are shown in Table 3.
Tests for hepatitis A virus, hepatitis B virus, hepatitis E
virus, cytomegalovirus, Epstein–Barr virus and HCV
RNA were performed and all the results were negative.
The episode of acute hepatitis began to resolve spon-
taneously. While she was hospitalized, however, her
serum creatinine level began to rise, with 3þ protein-
uria detected by urinary dipstick. She had hematuria
with dysmorphic red blood cells and cellular casts
containing leukocytes and erythrocytes on microscopic
examination of her urine.
Her blood urea nitrogen level peaked at 59 mg/dl
and her serum creatinine level peaked at 1.65 mg/dl.
The results of cryocrit, double-stranded DNA, and
rheumatoid factor tests were all negative. Her com-
plement C3 level was 74 mg/dl (reference range 81–157Kidney International Reports (2016) 1, 135–143mg/dl), and her C4 level was 14 mg/dl (reference range
12–39 mg/dl).
She underwent an ultrasound-guided renal biopsy
that showed 19 nonsclerotic glomeruli, all showing
marked endocapillary hypercellularity characterized
by endothelial cell swelling, intracapillary neutrophils
and macrophages, apoptotic debris, and mild mesangial
hypercellularity. A single pseudothrombus was seen in
1 glomerulus. This was associated with moderate
tubulointerstitial nephritis. Rare red cell casts were
seen. Focal vasculitis was present. There was no glo-
merulosclerosis or chronic vascular disease. Interstitial
ﬁbrosis and tubular atrophy were minimal. Immuno-
ﬂuorescence showed granular mesangial and glomer-
ular basement membrane (GBM) staining for IgG,
IgA, IgM, C3, C1q, and kappa and lambda light chains.
Immunoﬂourescent staining of the tubular basement
membranes and vessels were negative. Many mesan-
gial, paramesangial, and subendothelial electron-dense
deposits without substructure were present. Tubulor-
eticular inclusions were seen. These features were
consistent with an acute immune complex glomerulo-
nephritis with a lupus-like pattern of immune complex
deposition (Table 4 and Figure 2a, d, and g).
She began receiving on i.v. methylprednisolone, 500
mg daily for 3 days, and was then transitioned to pred-
nisone 60 mg (1 mg/kg). This resulted in the normaliza-
tion of her serum creatinine level (0.8 mg/dl) over the
next 3 weeks. At the same time, however, she indicated
that she had begun feeling confused and anxious; she
was found to have a plasma ammonia level of 165 mmol/l137
Table 3. Comparison of autoimmune serologic ﬁndings before and
after DAA treatment
Case Baseline serologic ﬁndings Post-DAA serologic ﬁndings
1 Cryoglobulin: negative
Remainder not available
ANA: 1:320
Ds-DNA: negative
Anti-histone: ND
Anti-RNP: negative
Anti-Smith: negative
Complement levels
C3: 74 (low)
C4: 14
Cryoglobulin: negative
Rheumatoid factor: Negative
Anti–smooth muscle Ab: 1:80
ANCA: Negative
2 ANA: 1:640 in 2007
Cryoglobulin: negative
Rheumatoid factor: Positive in 2007
Remainder not available
ANA: >1:5120
Ds-DNA: Positive 1:80
Anti-histone: >7.0
Anti-Ro/La: negative
Anti-Smith: negative
Complements levels
C3: 54
C4: 9 (low)
Cryoglobulin: negative
Rheumatoid factor: negative
3 ANA: 1:160
Ds-DNA: negative
Anti Ro/La: negative
Anti-Smith: negative
Cryoglobulin level: 5%
Complement levels
C3: 87
C4: 20 (normal)
Rheumatoid factor: negative
Remainder not available
ANA: 1:160
Ds-DNA: Negative
Anti-histone: 1.5 Units
Anti Ro/La: positive
Anti-Smith: Negative
Cryoglobulin level: 1%
Complement levels
C3: 42 (low)
C4: 7 (low)
Rheumatoid factor: negative
Ab, antibody; ANCA, antineutrophil cytoplasmic antibody; ANA, antinuclear antibody;
DAA, direct-acting antiviral; Ds-DNA, double-stranded DNA; ND, not done; RNP,
ribonucleoprotein.
Normal range for complements levels: C3, 81–157 mg/dl; C4, 12–39 mg/dl. Normal range
for antihistone antibody, <1.0 U.
Table 4. Summary of pathologic characteristics
Parameter Case 1 Case 2 Case 3
Light microscopy
Number of glomeruli 19 9 33
Global
glomerulosclerosis
0% 67% 9%
Segmental
glomerulosclerosis
0% 0% 0%
Endocapillary
hypercellularity
þþþ þþ þþþ
Pseudothrombi þ – –
Mesangial
hypercellularity
þ þþ þþ
Segmental GBM
duplication
þ þ þþþ
Crescents – – –
Fibrosis and tubular
atrophy
<5% w50% 20%
Interstitial
inﬂammation
þ þ 
Tubular injury  þ þ
Vascular disease   þþ
Vasculitis þ hilar arteriole – –
Immunoﬂuorescence microscopy results
Glomeruli
IgG þþ þþ þþþ
IgA þþ þþþ þþþþ
IgM þ þþ þþ
C3 þþþ þþ þþþ
C1q þþ þþþ 
Fibrin – – þþþ
Kappa light chain þþ þþþ þþþ
Lambda light
chain
þþ þþþ þþþþ
Tubules – Focal, broad linear
IgG and granular
C3
–
Interstitium – – –
Vessels – focal C3 focal C3
Electron microscopy
Foot process
effacement
segmental global segmental
Electron-dense
deposits
mesangial,
paramesangial,
subendothelial
mesangial,
paramesangial,
subendothelial,
intramembranous
mesangial,
subendothelial, and
intramembranous
Substructure – – –
Tubuloreticular
inclusions
þ þþþ –
GBM duplication  þ þþþ
Tubular basement
membrane
deposits
– – –
GBM, glomerular basement membrane.
In case 3,  staining for C1q indicates present but minimal staining.
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decompensation with lactulose and rifaximin, resulting
in resolution of encephalopathy. During this hospitali-
zation, ascites and a urinary tract infection were diag-
nosed, and the patient was subsequently treated with
ceftriaxone and discharged to a rehabilitation facility.
Over the next 4 days leukocytosis, hyponatremia,
decreased urinary output, abdominal pain, and rising
serum creatinine level (a rise from 0.77 mg/dl to 0.95 mg/
dl) developed, and she was transferred back to the hos-
pital. She was again given ceftriaxone for presumed
urinary tract infection due to hematuria and leukocy-
turia, although urine cultures demonstrated no growth.
During her hospital stay, she had persistent leukocytosis
and a chest radiograph revealed a right lower lobe
opacity for which she began treatment with i.v. vanco-
mycin and piperacillin-tazobactam; prednisone was
rapidly tapered. Her serum creatinine level began to rise
and peaked at 1.3 mg/dl. Vancomycin was stopped on
account of elevated trough values (37mg/ml [upper limit
of normal 20 mg/ml]), and her creatinine level stabilized.
She was discharged to a rehabilitation hospital. How-
ever, 48 hours later she was readmitted to the medical138intensive care unit with hypoxic reparatory failure and
septic shock due to pneumonia with empyema and oli-
guric acute kidney injury with a serum creatinine level
of 2.34 mg/dl secondary to presumed acute tubular ne-
crosis. She was intubated and placed on continuous
venovenous hemoﬁltration on account of acidosis and
worsening volume overload. Cultures from a bronchial
alveolar lavage and of the pleural ﬂuid revealed growthKidney International Reports (2016) 1, 135–143
Figure 2. Lightmicroscopyof the 3casesof immunecomplex–mediatedglomerulonephritis. Thecases showvaryingdegreesof glomerular activity from
(a) global endocapillary hypercellularitywith endothelial cell swelling, intracapillarymononuclear cells, neutrophils, and apoptotic debris (case 1) and (b)
segmental endocapillary hypercellularity and moderate mesangial hypercellularity (case 2) to (c) global endocapillary and mesangial hypercellularity
with double contours (case 3). A full house immunoﬂuorescence patternwas present in all cases (case 3 had only minimal C1q). (d) Granular glomerular
basement membrane (GBM) and segmental mesangial staining for C3 (case 1). (e) Granular mesangial and segmental GBM staining for IgG (case 2). (f)
Global granular mesangial and GBM staining for IgG (case 3). Electron microscopy showing (g) subendothelial and mesangial electron-dense deposits
and activated endothelium in a glomerular capillary loop (case 1) and (h,i) mesangial and paramesangial deposits (cases 2 and 3, respectively).
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however, she died the following day.
Case 2
The second patient is a 56-year-old white female with
HCV genotype 1b infection who had received a liver
transplant because of hepatocellular carcinoma in 2009
(Figure 1b and Tables 2 and 3). Before receiving the
transplant, she was treated with pegylated IFN and RBV
with an initial response followed by a relapse after
completion of therapy. Cirrhosis developed in the
transplanted liver and was complicated by chronic as-
cites and hepatic encephalopathy that were controlled
medically. Her Model for End-Stage Liver Disease score
was 17, Child-Pugh class B. At baseline she had chronic
kidney disease stage 3 with a serum creatinine ranging
from 1.4 to 1.7 mg/dl and an estimated glomerular
ﬁltration rate of 31 to 38 ml/min per 1.73m2 without
signiﬁcant proteinuria, hematuria, or leukocyturia
detected on pretreatment urinalysis. Her renal insufﬁ-
ciency had been attributed to chronic calcineurin use
and decompensated cirrhosis (hepatorenal syndrome
type II), although a biopsy had not been performed. She
began therapy with SOF, 400 mg daily, and RBV, 200
mg twice daily (dose reduced for her renal dysfunc-
tion), for 24 weeks. Her other medications included
allopurinol 100, mg twice daily; trimethoprim/sulfa-
methoxazole, single-strength tablet once daily; bume-
tanide, 2 mg twice daily; colchicine; 0.6 mg daily;
cyclosporine, 25 mg twice daily; erythropoietin, 2000
units weekly; labetalol. 200 mg 3 times per day; lactu-
lose, 30 ml 3 times per day; magnesium oxide, 800 mg
twice daily; metolazone, 5 mg daily; omeprazole, 20 mg
twice daily; potassium chloride extended release, 40
milliequivalents daily; and rifaximin, 550 mg twice per
day.
Her viral load was undetectable by week 4 of
treatment and remained undetected for the duration of
therapy. Her serum creatinine ﬂuctuated between 1.2
and 1.9 mg/dl throughout therapy. Her RBV was dose
reduced to 200 mg once daily because of development
of anemia. While receiving treatment she complained of
new onset of joint pain involving her hands and wrists,
decreased mobility, and worsening lower extremity
edema and ascites. Two weeks after completing ther-
apy, she was referred to a nephrologist when it was
discovered that her serum creatinine level had risen to
2.6 mg/dl and her urinalysis showed leukocytosis and
trace proteinuria on dipstick. Urine microscopy was
notable for the presence of white blood cell casts.
A serologic proﬁle was notable for a positive antinu-
clear antibody test result with a titer >1:5120 and a
histone antibody test result positive at >7.0 Units and
double-stranded DNA antibody positive at a 1:10 titer.140Her complement levels were low; her C3 level was 54
(reference range 81–157 mg/dl) and her C4 level was
was 9 (reference range 12–39 mg/dl). Cryoglobulins
were not detected in her serum. The results of all
available serological tests before and after treatment are
shown in Table 3.
She underwent a renal biopsy that showed mild
endocapillary hypercellularity characterized by intra-
capillary mononuclear cells and swollen endothelial
cells and moderate mesangial hypercellularity. Focal
GBM duplication was present. There was moderate
tubulointerstitial inﬂammation. Leukocyte and gran-
ular casts were seen. There was no vasculitis. Immu-
noﬂuorescence showed granular mesangial and GBM
staining for IgG, IgA, IgM, C3, C1q, and kappa and
lambda light chains. Mesangial, paramesangial, sub-
endothelial, and intramembranous electron-dense de-
posits without substructure were present. Many
tubuloreticular inclusions were seen. These ﬁndings,
along with the clinical features, supported an active
immune complex–mediated glomerulonephritis with a
lupus-like pattern of immune complex deposition.
There was also a background of moderate glomerular
and tubulointerstitial scarring, possibly from chronic
injury from hepatorenal syndrome (Table 4 and
Figure 2b, e, and h).
She was treated with methylprednisolone 250 mg i.v.
for 3 days, followed by prednisone, 60 mg daily (1 mg/
kg), andmycophenolate mofetil, 500 mg twice daily. Her
renal function rapidly improved and serum creatinine
decreased to 1.40 mg/dl within 3 days. Signiﬁcant
delirium and agitation developed, and the dose of
prednisone was rapidly decreased to 20 mg daily and
then tapered by 5 mg/wk. Because of the tubulointer-
stitial inﬂammation, trimethoprim/sulfamethoxazole
and allopurinol were permanently discontinued. At time
of discharge 1 week after kidney biopsy, the serum
creatinine level improved to 1.0mg/dl and then returned
to 1.4 mg/dl once diuretics were reintroduced. Delirium
resolved and the patient reported improvement in joint
pain and increased mobility. Unfortunately, the HCV
viral load became detectable 4 weeks after treatment,
indicating relapse. Three months later, she began
receiving on SOF, 400 mg, plus ledipasvir, 90 mg, ﬁxed-
dose combination therapy with the addition of RBV, 200
mg, every alternate day for 12 weeks. However,
approximately 8 weeks into therapy, her joint pain
relapsedwith prominent synovitis in the bilateralwrists,
metacarpal joints, and knees, and she required a course
of prednisone therapy starting at 40 mg and tapered by
10 mg every 2 weeks. Mycophenolate mofetil was dis-
continued. Azathioprine was substituted as a steroid-
sparing agent; however, her joint pain continued, so
she was switched back to mycophenolate mofetilKidney International Reports (2016) 1, 135–143
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improved and there was no evidence of relapse of
glomerulonephritis. Her viral load was negative, indi-
cating cure of HCV infection. She continues to receive
mycophenolate mofetil, 500 mg twice daily, and low-
dose prednisone that is slowly being tapered. She is
without joint pain or worsening renal function.
Case 3
The third patient is a 48-year-old Hispanic female with
a medical history of HCV genotype 1 infection and
cirrhosis who was initiated on a 12-week course of
DAA therapy with SOF, 400 mg ,and simeprevir, 150
mg daily (Figure 1c and Tables 2 and 3). She had
contracted HCV infection at age 18 and her medical
history included idiopathic thrombocytopenic purpura
treated by splenectomy in her mid-20s and systemic
lupus erythematous diagnosed in 1998 (at age 31) that
had been precipitated by IFN alfa use for HCV infec-
tion. Lupus manifestations included hemolytic anemia;
arthritis of the hands, knees, and ankles; and central
nervous system manifestations, including headache,
vertigo, and diplopia. Initially, she had multiple ﬂares
and had been treated with azathioprine, hydroxy-
chloroquine, and prednisone until 2009. At that point,
because of disease quiescence, prednisone and azathi-
oprine were discontinued and she continued to receive
hydroxychloroquine, 200 mg daily. She continued to
have quiescent disease and did not experience a lupus
ﬂare between 2009 and when DAAs were started in
2014. A diagnosis of cirrhosis was made clinically on
the basis of recent imaging showing a nodular liver.
She was listed for a liver transplant and had a Model
for End-Stage Liver Disease score of 11, Child-Pugh
class B, before beginning DAA therapy. Her baseline
serum creatinine level was 0.95 mg/dl, which corre-
sponded to an estimated glomerular ﬁltration rate of 67
ml/min per 1.73m2. Her other medications included
aspirin, 81 mg daily, clonidine, 0.1 mg twice per day,
folic acid, 1 mg daily, furosemide, 80 mg daily,
hydroxychloroquine, 200 mg daily, spironolactone, 50
mg daily, and valsartan 320, mg daily.
Two weeks into DAA treatment a triangular dark red
plaque on the upper chest with hemorrhagic small bulla
on the inferior edge, and erythema and erosions around
the nose and cheeks developed along with erythematous
and edematous plaques on the lateral part of the wrists
and thumbs after a brief exposure to the sun, and shewas
treated with topical steroids. During the fourth week of
DAA treatment, she complained of several days of
increased somnolence, fatigue, lower abdominal and
back discomfort, and dark urine. Laboratory studies
demonstrated a rise in serum creatinine level to 1.43 mg/
dl and her urinalysis showed red blood cells, white bloodKidney International Reports (2016) 1, 135–143cells, and hyaline casts. She was referred to the emer-
gency department, where she was treated empirically
with i.v. hydration and ciproﬂoxacin for presumed py-
elonephritis, although the results of a urine culture were
later negative. Her serum creatinine level decreased from
1.43 mg/dl to 1.11 mg/dl and she was discharged with a
10-day prescription of ciproﬂoxacin. Furosemide and
spironolactone were temporarily discontinued. Four
weeks later, after a total of 9 weeks of DAA therapy she
again presented to the hepatologist with back pain and
dark urine. Laboratory studies were notable for hyper-
bilirubinemia (5.4 mg/dl), prolonged prothrombin time
(international normalized ratio 1.7), hypoalbuminemia
(1.8 g/dl), and a serum creatinine level of 1.45mg/dl. SOF
and simeprevir were discontinued at this time and she
was treated with 2 additional courses of antibiotics for
possible urinary tract infection. Because of persistent
elevation of her serum creatinine level, hematuria, and
proteinuria, she underwent renal biopsy.
The renal biopsy showed enlarged, lobular glomeruli
with marked endocapillary with intracapillary mono-
nuclear cells and marked mesangial hypercellularity
and expansion. The GBMs were thickened and showed
double contours. There was no tubulointerstitial
inﬂammation and no vasculitis. Immunoﬂuorescence
microscopy showed granular mesangial and GBMs
staining for IgG, IgA, IgM, C3, C1q, kappa and lambda
light chains, and ﬁbrinogen. Numerous large and
conﬂuent subendothelial, mesangial, paramesangial and
intramembranous electron dense deposits were present
and did not show substructures. These ﬁndings were
consistent with a severe active and chronic immune
complex–mediated glomerulonephritis resembling a
diffuse proliferative lupus nephritis (Table 4 and
Figure 2c, f, and i).
Her serologic work-up results were notable for a
positive antinuclear antibody test result at a titer of
1:160, her histone antibody level was 1.5 U, her cry-
oglobulin percentage was 1%, and she had low serum
complement (C3 and C4) levels (Table 3). Serum HCV
RNA was undetectable more than 3 months after
completion of therapy, indicating that HCV had been
eradicated despite the fact that her regimen had been
shortened to 9 weeks. Three weeks after the renal bi-
opsy, after completing the antibiotic course prescribed
to treat a positive urine culture demonstrating Klebsi-
ella infection, she was given a pulse dose of methyl-
prednisolone, 250 mg i.v. for 3 days, and then
transitioned to prednisone 60 mg daily (1 mg/kg) fol-
lowed by weekly rituximab infusions for 3 doses. Her
serum creatinine stabilized at 2.3 mg/dl and she was
discharged.
However, 1 week later she presented to the hospital
with lethargy and back pain and was admitted to the141
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Serratia bacteremia with pancolitis seen on imaging.
Oliguric acute kidney injury developed, and she
required continuous venovenous hemoﬁltration. She
had progressive respiratory failure from Steno-
trophomonas pneumonia and required intubation. Her
liver function worsened, disseminated intravascular
coagulation developed, and she died on day 30 of
hospitalization.DISCUSSION
Autoimmune phenomena are well-described complica-
tions of IFN-based therapies for HCV infection. Here we
have described 3 cases of lupus-like immune complex
glomerulonephritis with “full house” immunoﬂuores-
cence in patients with cirrhosis who were treated with
IFN-free all-oral DAA regimens. It is possible that this
autoimmune phenomenon represents an immune recon-
stitution syndrome. In the ﬁrst 2 cases, these patients had
no known autoimmune history, nor suggestive symp-
tomsbefore initiation ofDAAs. Case 2 had a prior positive
antinuclear antibody test result (Table 3) that was per-
formed as a part of routine evaluation before liver
transplantation and was not due to suggestive clinical
symptoms. In the third case, DAA therapy rapidly
aggravated the patient’s preexisting IFN alfa–induced
lupus that had beendiagnosed 17years prior. In this case,
the timing of symptom onset and the fact that her disease
had been clinically quiescent for more than 5 years sug-
gest that clearance of her HCV aggravated preexisting
autoimmunity. In this case C1q was minimal and tubu-
loreticular inclusionswere not detected, in contrast to the
majority of cases of lupus nephritis.12 Lupus nephritis is
generally characterized by immune deposits that stain
dominantly or codominantly for IgG. In this series,
although IgG staining was strong, it was not dominant
(Table 4).We note that IgAwas codominant in case 2 and
3 and that this may be due to known association of
mesangial IgA deposition in advanced liver disease.13–15
Two patients received SOF paired with RBV and 1
received SOF and simeprevir; the fact that this
occurred with the use of agents that purely target steps
in the HCV life cycle raises the possibility that an
autoimmune diathesis was unmasked with removal of
HCV, even in the absence of IFN or RBV use. It is
tempting to speculate, given the known effects of
chronic HCV on suppression of host IFN responses, that
removal of viral antigen in otherwise predisposed pa-
tients may elicit sensitivity to endogenous IFN effects
and resultant unmasking of autoimmunity.16,17 Two of
the 3 patients had antihistone antibody titers deter-
mined and in both cases this autoantibody was detec-
ted in the serum (Table 3). Although a drug-induced142lupus may be an alternative explanation in these pa-
tients with presence of antihistone antibodies, in 1 of
the cases with a positive antihistone antibody test
result, systemic lupus erythematous had been a long-
standing condition. However, drug-induced lupus is
only rarely associated with glomerulonephritis. In case
2, the recurrence of severe joint pain during retreat-
ment with SOF/ledipasvir and RBV strengthens the
relationship between treatment and emergence of
lupus-like symptoms. Finally, all patients had remote
previous exposures to IFN; it is possible that a smol-
dering lupus syndrome existed but was not clinically
detected; however, the dramatic emergence of symp-
tomatic lupus with both renal and nonrenal manifes-
tations in all cases (Table 2) argues for the relationship
between IFN-free DAA treatment and disease.
Although the pattern of glomerular injury seen in
lupus nephritis and mixed cryoglobulinemia can result
in identical morphological changes, the lack of sub-
structures in the deposits by electron microscopy in all
cases, absence of large intracapillary deposits in the
glomeruli (pseudothrombi), and negative HCV RNA
test result at the time of biopsy for all cases favors a
lupus-like nephritis over an HCV-associated immune
complex disease. Furthermore, HCV-associated renal
disease typically improves with HCV eradication.18–22
All 3 patients experienced rapid improvement in
serum creatinine level with the initiation of high-dose (1
mg/kg) corticosteroids with or without the addition of
other immunosuppressive agents (Figure 1a–c). All 3
experienced normalization of serum creatinine level
within 1 to 3 weeks. Unfortunately, 2 of the 3 patients
died of infectious complications while receiving high-
dose steroids. The lone surviving patient had been
rapidly tapered off steroids early in her course on account
of delirium and was maintained on low-dose mycophe-
nolate for 3 to 6 months, which suggests that this
glomerular lesion may respond to a short course of ste-
roids; it is unclear whether or not maintenance therapy is
needed. The lone surviving patient continues to receive
mycophenolate mofetil to manage joint pains and to
prevent relapse of glomerulonephritis. Thus, a key take-
away point from this series is that these patients, who
each had baseline cirrhosis in addition to new-onset
glomerulonephritis, are susceptible to adverse outcomes
from immunosuppression. Recent evidence in the liter-
ature highlights the occurrence of severe infections after
treatment with rituximab in patients with kidney dis-
ease.23–25 Thus, aggressive immunosuppressive therapy
should be used in these cases with extreme caution,
particularly if cirrhosis is present.
Wehave reported 3 cases of immune complex–mediated
glomerulonephritis with full house immunoﬂuorescence
occurring in patients being treated for HCV with novelKidney International Reports (2016) 1, 135–143
ME Sise et al.: Immune Complex-Mediated Glomerulonephritis NEPHROLOGY ROUNDSall-oral direct-acting antiviral therapies who presented
with joint pain or rash in addition to hematuria, pyuria,
and rising creatinine level. This phenomenon was not re-
ported in phase II/III studies and appears to have affected a
very small minority of the patients treated in our health
care system. Although this possible reaction is rare, it is
important that HCV providers and nephrologists be aware
of it and consider kidney biopsy in any patient with
worsening renal function, proteinuria, or development of
activeurine sedimentduringor after treatmentwithDAAs.
Further study is needed to determine the mechanism of
autoimmunity in patients treated with IFN-free regimens.
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